Phenotypes of heart failure with preserved ejection fraction and effect of sodium-glucose cotransporter 2 inhibitors treatment

31 August 2025 (17:15 - 18:00)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Mrs Ayano Sezaki

Nippon Medical School Hospital, Tokyo (Japan)

9 More presentations in this session

Presentation thumbnail

Efficacy of sodium-glucose cotransporter 2 inhibitors for super-aged heart failure population

Doctor J. Noiri (Kobe, JP)

Abstract Slides Video

Presentation thumbnail

The relevant role of frailty in patients with transthyretin amyloidosis cardiomyopathy

Doctor B. Dal Passo (Ferrara, IT)

Abstract Slides Video

Presentation thumbnail

Role of comorbidities and weight variations in the survival of diabetic patients with heart failure

Professor O. Hanon (Paris, FR)

Abstract Slides Video

Presentation thumbnail

Angiotensin receptor-neprilysin inhibitor-based therapy among adult heart failure patients with below normal systemic ventricular ejection fraction and complex congenital heart disease

Doctor D. Dela Cruz (Metro Manila, PH)

Abstract Slides Video

Presentation thumbnail

The effects of empagliflozin on ventricular arrhythmias in heart failure patients with an implantable cardioverter-defibrillator: a systematic review

Doctor M. Hunjul (Nablus, PS)

Abstract Slides Video

Access the full session

Session thumbnail

Heart failure management in specific populations

The Event

Event poster

ESC Congress 2025

31 August 2025 17:15 CET

You may be interested in

Congress Presentation

Which phenotypes in Asia?

Congress Session

Clinical phenotype profiling in heart failure with preserved ejection fraction

Congress Presentation

Heart failure with preserved ejection fraction: who are our patients?

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources